CYP2D6 genotype in relation to perphenazine concentration and pituitary pharmacodynamic tissue sensitivity in Asians: CYP2D6–serotonin–dopamine crosstalk revisited

OBJECTIVESHyperprolactinemia is a common side effect of first-generation antipsychotics mediated by antagonism of dopaminergic neurotransmission in the pituitary. Most first-generation antipsychotics are metabolized by CYP2D6 in the liver. Further, CYP2D6 is expressed in the human brain as a 5-metho...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pharmacogenetics and genomics 2007-05, Vol.17 (5), p.339-347
Hauptverfasser:	Ozdemir, Vural, Bertilsson, Leif, Miura, Jun, Carpenter, Erin, Reist, Christopher, Harper, Patricia, Widén, Jolanta, Svensson, Jan-Olof, Albers, Lawrence J, Kennedy, James L, Endrenyi, Laszlo, Kalow, Werner
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antipsychotic Agents - pharmacology Biological and medical sciences Cytochrome P-450 CYP2D6 - genetics Cytochrome P-450 CYP2D6 - metabolism Dopamine - pharmacology Dopamine Agents - pharmacology Double-Blind Method Drug Interactions Female General pharmacology Genotype Homozygote Humans Male Medical sciences Medicin och hälsovetenskap Perphenazine - pharmacology Pharmacokinetics. Pharmacogenetics. Drug-receptor interactions Pharmacology. Drug treatments Pituitary Gland - drug effects Pituitary Gland - metabolism Placebos Polymorphism, Genetic Prolactin - metabolism Prospective Studies Serotonin - pharmacology Serotonin Agents - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!